Doctors harvest stem cells from the patient’s bone marrow and then send them off to a lab, where CRISPR is used to turn up the production of another, functional version of haemoglobin. This version is ...

Like recombinant DNA before it, gene editing has the potential to transform medicine, agriculture and more. CRISPR is now used by thousands of biologists in labs across the globe. A revolution in food ...

Bluebird bio went public in 2013, raising approximately $116m through its IPO. The company has developed three US Food and Drug Administration (FDA)-approved gene therapy products, including Zynteglo ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started, either. Here are two no-brainer healthcare stocks to buy with $500 right ...

CRISPR Therapeutics (CRSP) stock slips after a strong rally driven by earnings beats and analyst upgrades. Explore future catalysts and investment insights.

In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.

In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

An SCD patient in Bahrain received the gene-editing therapy Casgevy, marking the first time the treatment has been given outside the U.S.

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.